- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01431664
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young patients with relapsed or refractory acute leukemia.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
OBJECTIVES:
Primary
- To identify the maximum-tolerated dose and recommended phase IIb dose of multikinase inhibitor AT9283 in pediatric patients with relapsed or refractory acute leukemia.
Secondary
- To evaluate the safety and tolerability of this drug in these patients.
- To document evidence of efficacy of this drug in these patients.
- To investigate the pharmacokinetic profile of this drug in plasma in these patients.
Tertiary
- To assess target kinase inhibition by multikinase inhibitor AT9283 in these patients.
- To identify potential predictive molecular biomarkers in these patients.
OUTLINE: This is a multicenter study.
Patients receive multikinase inhibitor AT9283 IV continuously over 72 hours. Treatment repeats every 21 days* for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving benefit of treatment may continue for up to 6 more courses at the discretion of the chief/principal investigator.
NOTE: *Course length may be extended to a maximum 42 days to allow for recovery of blood counts. Intrathecal therapy is permitted from course 2 onwards in patients with ALL.
Blood specimens are collected for pharmacokinetic and pharmacodynamic studies including molecular predictive biomarkers and ex vivo and in vivo measurement of kinase inhibition assessments.
After completion of study treatment, patients are followed up for 42 days or until recovery of blood counts (whichever is the sooner).
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Birmingham,, Regno Unito, B4 6NH
- Birmingham Children's Hospital
-
Leeds, Regno Unito, LS1 3EX
- Leeds General Infirmary
-
Manchester, Regno Unito, M13 9WL
- Royal Manchester Children's Hospital
-
Newcastle upon Tyne, Regno Unito, NE1 4LP
- Great North Children's Hospital, Royal Victoria Infirmary
-
-
London
-
Surrey, London, Regno Unito, SM2 5PT
- Royal Marsden Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Histologically confirmed acute leukemia according to the following criteria:
Acute lymphoblastic leukemia (ALL) meeting any of the following criteria:
- Second relapse
- Refractory to induction therapy for first relapse
- Third or subsequent relapse
Acute myeloid leukemia (AML) meeting any of the following criteria:
- Second or subsequent relapse
- Refractory to an induction therapy for first relapse
- Without a curative treatment option
Other type of acute leukemia meeting any of the following criteria:
- First or subsequent relapse
- Refractory to induction therapy
- Not eligible for any therapy of higher curative potential
- No chronic myeloid leukemia (CML)
- Patients in relapse must have ≥ 5% blasts in the bone marrow
- Patients with refractory disease following induction must have ≥ 20% blasts in the bone marrow
- No evidence of CNS disease
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 50-100% OR Lansky PS 50-100%
- Life expectancy ≥ 8 weeks
- Serum bilirubin < 1.5 times upper limit of normal (ULN)
- ALT or AST < 2.5 times ULN (5 times ULN if due to leukemic infiltration of the liver)
- Creatinine clearance ≥ 60 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile female patients must use 2 of the following combined forms of contraception (oral, injected, or implanted hormonal contraception and condom OR intra-uterine device and condom OR diaphragm with spermicidal gel and condom) before, during, and for 6 months after completion of study therapy
Male patients must use 1 form of highly effective contraception (condom plus spermicidal gel) during and for 6 months after completion of study therapy
- Men with pregnant or lactating partners should be advised to use barrier-method contraception (condom plus spermicidal gel)
- No serological positivity for hepatitis B, hepatitis C, or HIV
- No congenital heart disease, with the exception of patent foramen ovale or small muscular ventricular septal deficit (within the first year of life)
- No uncontrolled arterial hypertension (defined as a systolic blood pressure [BP] and/or diastolic BP ≥ 95th percentile for age and height)
- No fractional shortening of ≤ 29% on echocardiogram
- No active graft-vs-host disease
No current non-malignant systemic disease considered high medical risk, including any of the following:
- Active uncontrolled infection
- Unstable or uncompensated respiratory or cardiac condition that makes study participation undesirable
- No other condition that, in the Investigator's opinion, would not make the patient a good candidate for the clinical trial
PRIOR CONCURRENT THERAPY:
Recovered from toxicity of prior therapy, including toxicity following hematopoietic stem cell transplantation
- Alopecia or certain grade 1 toxicities allowed at the discretion of the Investigator
- A maximum of 2 days of hydroxycarbamide 10-20 mg/kg/day (or according to local practice) in patients with AML and hyperleukocytosis allowed
- At least 7 days since prior investigational drugs (except antibodies for which a 4-week window must be observed)
At least 7 days since prior protein kinase inhibitors and intrathecal therapy
- Concurrent intrathecal therapy allowed from course 2 onwards in patients with ALL
- At least 14 days since prior cytotoxic therapy, including vincristine and other anti-neoplastics
- No prior major thoracic or abdominal surgery from which the patient has not yet recovered
- No prior aurora kinase inhibitor
No concurrent steroid therapy
- Multikinase inhibitor AT9283 administration may be commenced once steroids have started; however, steroids may not be started once multikinase inhibitor AT9283 has started
- Up to 5 days of prior oral dexamethasone (6 mg/m^2) for patients with ALL experiencing a rapid rise in blast count allowed
No other concurrent interventional clinical study
- Participation in an observational study allowed
- No other concurrent anticancer therapy or investigational drugs
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Mascheramento: Nessuno (etichetta aperta)
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
---|
Maximum-tolerated dose and recommended phase II dose of multikinase inhibitor AT9283
|
Misure di risultato secondarie
Misura del risultato |
---|
Adverse events to multikinase inhibitor AT9283 and grading severity according to NCI CTCAE Version 4.02
|
Partial remission, complete remission, or complete remission with incomplete bone marrow recovery using disease-specific criteria based on ANC, platelets, and % blasts in the bone marrow
|
Plasma concentration measurement of multikinase inhibitor AT9283
|
Tertiary outcome(s) - Ex vivo and in vivo measurement of kinase inhibition using Plasma Inhibitory Activity (PIA) assay, phosphorylated STAT5 assay, and skin-punch biopsy (measuring pHH3, p53, PCNA, Ki67 levels)
|
Results of established and novel prognostic biomarkers (genetic mutations of JAK 1, 2, 3, FLT3, IKAROS, and BCR/ABL) linking to observed responses
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Josef Vormoor, Sir James Spence Institute of Child Health at Royal Victoria Infirmary
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CDR0000709775
- CRUK-CR0708-12
- EUDRACT-2009-016952-36
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su studio farmacologico
-
Digisight Technologies, Inc.SconosciutoRetinopatia diabetica | Degenerazione maculare legata all'età | MetamorfopsiaStati Uniti
-
St. Joseph's Healthcare HamiltonSospeso
-
University of MichiganCompletato
-
University of MichiganCompletatoTelemedicinaStati Uniti
-
AstraZenecaCompletatoCancro al seno | Oncologia | EpidemiologiaAlgeria
-
University of MichiganAttivo, non reclutanteDepressione | Attività fisica | Sonno | Stato d'animoStati Uniti
-
Fonds de la Recherche en Santé du QuébecUniversité de MontréalCompletatoIpertensione | Diabete mellito, tipo 2 | Dislipidemie | Colesterolo, LDL | ComorbiditàCanada
-
University of MichiganCompletatoDepressione | Attività fisica | Sonno | Stato d'animoStati Uniti
-
Peking UniversityHuantai Maternal and Child Health Care HospitalSconosciutoDisfunzione gastrointestinale | Disturbi della nutrizione infantileCina
-
University of HawaiiNational Cancer Institute (NCI); National Institutes of Health (NIH); University...Reclutamento